Modulating the microbiota—particularly within the gut and tumor microenvironment—may also influence responses to cancer therapies, including chemotherapy and immune checkpoint blockade (PD-1, CTLA-4) [185,186]. The gene discussed is CTLA4; the disease is neoplasm.